<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="t1-kjp-2019-01116" orientation="portrait" position="float">
 <label>Table 1.</label>
 <caption>
  <p>Comparison of direct-acting antiviral and peginterferon plus ribavirin in children</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="left" valign="middle" rowspan="1" colspan="1">Variable</th>
    <th align="center" valign="middle" rowspan="1" colspan="1">DAA</th>
    <th align="center" valign="middle" rowspan="1" colspan="1">PegIFN + ribavirin</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td valign="top" align="left" rowspan="2" colspan="1">Administration </td>
    <td valign="top" align="left" rowspan="2" colspan="1">Oral </td>
    <td valign="top" align="left" rowspan="1" colspan="1">PegIFN: subcutaneous injection (per week)</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Ribavirin: oral</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Cost</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Most expensive, cost-effective by insurance coverage</td>
    <td valign="top" align="left" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Treatment duration</td>
    <td valign="top" align="left" rowspan="1" colspan="1">12 Weeks</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Genotype 1: 48 weeks; Genotype 2, 3: 24 weeks</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="2" colspan="1">Efficacy </td>
    <td valign="top" align="left" rowspan="1" colspan="1">SVR12</td>
    <td valign="top" align="left" rowspan="1" colspan="1">SVR24</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Pan-genotype: 98% to 100%</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Genotype 1: 53%; Genotype 2, 3: 93%</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="2" colspan="1">Available age </td>
    <td valign="top" align="left" rowspan="2" colspan="1">Sofosbuvir or ledipasvir/sofosbuvir ≥12 years (European Medicines Agency), ≥3 years (U.S. Food and Drug Administration) </td>
    <td valign="top" align="left" rowspan="1" colspan="1">PegIFN alfa-2b (PEG Intron): ages ≥ 3 years</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">PegIFN alfa-2a (Pegasys): ages ≥ 5 years</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="2" colspan="1">Adverse reactions</td>
    <td valign="top" align="left" rowspan="2" colspan="1">Minor</td>
    <td valign="top" align="left" rowspan="1" colspan="1">PegIFN: flu-like symptoms, neuropsychiatric symptoms, leukopenia, thyroid disease</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Ribavirin: hematological complication such as hemolytic anemia</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Contraindication</td>
    <td valign="top" align="left" rowspan="1" colspan="1">None</td>
    <td valign="top" align="left" rowspan="1" colspan="1">PegIFN: hypersensitivity reactions to interferon, hepatic decompensation (Child–Pugh class B, C)</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>DAA, direct-acting antiviral drug; PegIFN, peginterferon; SVR12, sustained virologic response at 12 weeks after treatment; SVR24, sustained virologic response at 24 weeks after treatment.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
